www.benzinga.com Open in urlscan Pro
151.101.66.137  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Get Benzinga Pro
 * Data & APIs
 * Events
 * Marketfy
 * Premarket
 * Boost
 * Advertise

Contribute
Español
India
Italiano
Sign in
 * Our Services
 * News
   Earnings
   Guidance
   Dividends
   M&A
   Buybacks
   Legal
   Interviews
   Management
   Offerings
   IPOs
   Insider Trades
   Biotech/FDA
   Politics
   Government
   Healthcare
 * Markets
   Pre-Market
   After Hours
   Movers
   ETFs
   Forex
   Cannabis
   Commodities
   Binary Options
   Bonds
   Futures
   CME Group
   Global Economics
   Mining
   Previews
   Small-Cap
   Real Estate
   Cryptocurrency
   Penny Stocks
   Digital Securities
   Volatility
 * Options
 * Ratings
   Analyst Color
   Downgrades
   Upgrades
   Initiations
   Price Target
 * Ideas
   Trade Ideas
   Covey Trade Ideas
   Long Ideas
   Short Ideas
   Technicals
   From The Press
   Jim Cramer
   Rumors
   Best Stocks & ETFs
   Best Penny Stocks
   Best S&P 500 ETFs
   Best Swing Trade Stocks
   Best Blue Chip Stocks
   Best High-Volume Penny Stocks
   Best Small Cap ETFs
   Best Stocks to Day Trade
   Best REITs
 * Money
   Investing
   Cryptocurrency
   Mortgage
   Insurance
   Yield
   Personal Finance
   Forex
   Startup Investing
   Real Estate Investing
   Credit Cards
 * Crypto
 * Cannabis
   Cannabis Conference
   News
   Earnings
   Interviews
   Deals
   Regulations
   Psychedelics
 * Jobs


Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research


My Stocks

Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
RecentMarkets

SPY

549.820.24%

QQQ

486.440.25%

SPIKE

12.752.57%

BTC/USD

65159.920.4099%

DIA

389.690.14%

GLD

216.740.59%

TLT

93.461.19%



COLORECTAL CANCER SURVIVAL RATE AFTER 5 YEARS IS 90% WITH EARLY DETECTION, YET
TESTING IS INACCESSIBLE FOR MANY – MAINZ BIOMED WANTS TO CHANGE THAT

by Meg Flippin, Benzinga Staff Writer



June 12, 2024 3:45 PM | 4 min read | Make a Comment

Partner Disclosure


Colorectal cancer is a leading cause of death in America, killing 50,000 people
each year. But if it’s caught early, the survival rate after five years is 90%.
Despite those favorable odds, only about four in 10 colorectal cancers are
spotted at the early stage. 

There are several reasons why more people aren't getting screened for this
devastating cancer. Some aren't aware that regular testing can save their lives,
many can't afford it, while others don't have access. Colonoscopies done at
ten-year intervals and occult blood tests (FITS) performed annually or
biannually are the two forms of screenings, but both have disadvantages.
Colonoscopies, while very precise, involve an unpleasant procedure and lengthy
intestinal cleansing. Occult blood tests are more widely accepted, but they can
only provide indirect evidence of disease and often only in later, bleeding
stages.




ADVANCED SCREENING EQUALS EARLY DETECTION 

To be effective, cancer screening has to be simple, readily available and
affordable, which is where Mainz Biomed MYNZ comes in. The molecular genetics
diagnostic company specializing in the early detection of cancer is
revolutionizing the colorectal cancer testing industry with ColoAlert, its
flagship product. 

ColoAlert is an early detection screening that spots bleeding and non-bleeding
tumors through tumor DNA analysis, offering what the company says is better
early detection than fecal occult blood tests. That's important since almost all
colorectal cancers develop from polyps that grow over time. The longer the
polyps are present, the higher the risk of them becoming cancerous, which is why
early screening has the potential to dramatically impact treatment and
prevention. 

Colorectal cancer originates from the genetic mutation of intestinal cells.
These are continuously excreted through the stool and can be examined for tumor
DNA using modern genetic diagnostic methods. ColoAlert analyzes samples for the
four tumor markers associated with cancer: KRAS-mutation, BRAF-mutation, total
amount of human DNA and occult blood. That's something competing at-home
screenings can't claim to do. 

By analyzing tumor DNA, Mainz says ColoAlert detects 85% of colorectal cancer
cases – often in the very early stages of the disease. That is a key
differentiator, given the company says 71% of the diagnoses made are in the
later stages of the disease.


MARKET OPPORTUNITY IS BROAD

If ColoAlert proves to be game-changing in terms of getting more people to
screen for colorectal cancer, it’s a big opportunity for Mainz. As it stands, 37
million people in the U.S. get screened for rectal cancer each year. That could
increase to 52 million per year within ten years as the population ages. 

In the United States there are 112 million people over 50, which is expected to
increase to 157 million in the next decade. Of the U.S. population between 50
and 75, about 40% have never been screened. While the common practice is to
start the screening at 50, the Food and Drug Administration says screening
should start at age 45 and be conducted every three years. If that guidance is
followed, it presents an even bigger opportunity for ColoAlert. All told, Mainz
pegs the U.S. opportunity at $4 billion and the European market opportunity at
$6 billion. 

ColoAlert is already proving to be more accurate than rivals' at-home tests,
which should drive adoption rates and help Mainz Biomed achieve its goals. A
recent multicentric study of 566 patients simultaneously using the occult blood
test, M2-PK test and ColoAlert, found ColoAlert, with a sensitivity of 85% and a
specificity of 92%, was the most accurate test result among the non-invasive
screening methods. The company plans to engage in further testing to validate
the effectiveness of its screening over what's already available in the market. 

"Combined DNA stool assay represents a reliable assay for detecting colorectal
cancer, sufficient to be recommended as a supplement to colonoscopy screening,"
the study researchers reported.


MAKING IT EASY 

On top of being accurate, ColoAlert is easy to use, which could be a big driver
of adoption. Within five minutes, the sample is collected and packaged and on
the way to the lab. Patients receive a kit in the mail that includes
instructions, a stool collector and a shipping label to return the kit to their
local lab for testing. Patients receive the results in a few days. Unlike the
rival ColoGuard, Mainz says ColoAlert requires very small samples to test, which
is one of the reasons the company boasts 98% patient satisfaction. 

Colorectal cancer is the third most commonly diagnosed cancer and a leading
cause of cancer death globally, but it doesn't have to be. Early detection means
all the difference, yet far too many people don't get screened each year. Mainz
is hoping ColoAlert will change that, helping to lower incidents of this and
other gastrointestinal cancers. 

To learn more about ColoAlert and the science behind it, click here. 

Featured photo by National Cancer Institute on Unsplash.

This post contains sponsored content. This content is for informational purposes
only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights
reserved.


Be the first to comment!

COMMENTS


Close menu
Loading...


Posted In: BiotechGeneralMainz BiomedPartner ContentPublic Company Sponsored

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports
and breaking news that affects the stocks you care about.

Join Now: Free!
Already a member?Sign in


--------------------------------------------------------------------------------


"ONE OF THE MOST SIGNIFICANT DEVELOPMENTS IN RAPID IN VITRO DIAGNOSTICS SINCE
ITS INVENTION" SAYS GEMINA LABS CEO ABOUT COMPANY'S REVOLUTIONARY TECHNOLOGY

by Meg Flippin, Benzinga Staff Writer


June 20, 2024 9:00 AM | 3 min read | Make a Comment

Partner Disclosure

Gemina Laboratories GLAB, the biosensor and diagnostic company focused on rapid
testing for respiratory and other pathogens that affect human health and
wellness, is making waves in the diagnostics sector thanks to its cutting-edge,
next-gen technology.  Under the leadership of CEO Brian Firth, formerly COO of
Swiss Precision Diagnostics and makers of the Clear Blue Pregnancy Test, Gemina
Laboratories says it is poised to transform the landscape of rapid testing for
respiratory diseases and beyond. It's a big market opportunity, given chronic
respiratory disease was the third-leading cause of death in 2019. Rapid testing
for it and other pathogens can reduce the spread of life-threatening illnesses
and help people get treated faster Gemina Labs specializes in the development of
unique binding technologies for the Point-of-Care (PoC) diagnostic industry.
Utilizing their proprietary chemistry, Gemina’s innovations reduce production
costs and improve the accuracy and the useability of diagnostic tests. The
company's “game-changing” chemistry is not only reserved for its own products.
Gemina Labs is also licensing it to other producers to incorporate into their
lateral flow technologies. “Our chemistry is one of the most significant
developments in rapid in vitro diagnostics since its invention. It reduces
production costs and improves accuracy,” says Firth Gemina Labs is in growth
mode, pursuing its vision to make affordable, rapid and lab-accurate PoC
diagnostics available worldwide. The company's cutting-edge technology and R&D
capabilities have drawn significant attention from leading biochemists,
healthcare professionals, academics and business leaders globally, including a
big global diagnostics company. Gemina Labs just signed a licensing agreement
with what it says is one of the leading players in the $106 billion global in
vitro diagnostics market. Gemina says the agreement marks a major validation of
its technology after a year of extensive scrutiny and evaluation by the
diagnostics company. “This is an outstanding first for Gemina,” said Firth. “We
are now targeting similar licensing deals with strategic partners across the
life sciences and medical device sectors to enable next-generation diagnostics
with our unique suite of proprietary technologies.” Looking ahead, Gemina Labs
is strategically positioning itself for further growth through additional
licensing deals and partnerships. The company's goal is to continue expanding
access to rapid, accurate diagnostics – making a positive difference in the
medical, healthcare, wellness and occupational health sectors. Gemina Labs isn't
your run-of-the-mill diagnostics company. It sees itself as a transformative
force with the potential to revolutionize how rapid diagnostics are developed
and deployed globally. Investors and industry stakeholders may want to keep an
eye on this potential rising star
Read More



--------------------------------------------------------------------------------




8 LARGE CAP STOCKS THAT OUTPERFORMED NVIDIA OVER THE PAST YEAR

by Surbhi Jain


June 19, 2024 1:02 PM | 3 min read | 1 Comment


ZINGER KEY POINTS

 * Eight large-cap stocks outperformed Nvidia over the past year across various
   sectors and industries.
 * Top performers include MicroStrategy, Carvana, Coinbase, Vertiv, Super Micro
   Computer, Vistra, AppLovin, and Insmed.


Nvidia Corp. NVDA has undeniably been one of the most remarkable success stories
in the stock market. The company’s staggering 591,078% return since its 1999
initial public offering, driven by strategic bets on graphics chips and
artificial intelligence technology, has catapulted it to the top of the tech
world. The stock has surged 217.58% over the past year, 173.78% year-to-date But
several other large-cap stocks have outperformed Nvidia over the past year. Here
are eight of them: Also Read: Here’s How Much You Should Have Invested In Nvidia
In 2022 To Become A Millionaire TodayImage: Shutterstoc
Read More



--------------------------------------------------------------------------------




TIKTOK TUNES? SOCIAL MEDIA PLATFORM HAS A MUSIC M&A TEAM IN THE WORKS

by Franca Quarneti, Benzinga Staff Writer


June 19, 2024 1:24 PM | 2 min read | 1 Comment


ZINGER KEY POINTS

 * TikTok's new Music Content Investment Team will explore global partnerships
   and acquisitions, further advancing its music industry presence.
 * MBW revealed TikTok's plans to invest in music rights, posing potential
   challenges for major record companies.


Two years ago, questions emerged about whether TikTok was evolving into a record
company. The video platform — owned by Beijing-based ByteDance Ltd. — launched
the SoundOn music distribution service and hired Artists & Repertoire
executives. On Tuesday, June 18, Music Business Worldwide (MBW) revealed that
TikTok is advancing this plan What Happened: TikTok is establishing a Music
Content Investment Team based in Los Angeles, New York, and San Jose. The team’s
goal is to explore global partnership or acquisition opportunities in the music
content sector See Also: Does TikTok Help The Music Industry? Study Shows
Increased Live Event Attendance, Spending Habits
Read More



--------------------------------------------------------------------------------


Loading...


EVERY STORY THAT MATTERS AROUND THE WEB

 * DeSantis Faces Backlash Over Email Blast To 2M People Including Medical
   Marijuana Patients Who Cite Privacy Concerns, Misuse Of Information
 * Elon Musk Reassures Advertisers By Revealing Why He Told Them To 'Go F***
   Yourself' Last November: 'I Do Shoot Myself In The Foot From Time To Time'
 * GameStop Insider Makes Over $58K On A Single Trade — Courtesy Roaring
   Kitty-Spurred Rally
 * Here's How Much You Should Have Invested In Nvidia In 2022 To Become A
   Millionaire Today
 * Nvidia To Acquire Shoreline.Io For $100M As Jensen Huang-Led AI Stalwart Aims
   To Cut Revenue Reliance On Microsoft, Amazon And More: Report
 * 8 Large Cap Stocks That Outperformed Nvidia Over The Past Year








POPULAR CHANNELS

 * PreMarket Prep
 * Press Releases
 * Analyst Ratings
 * News
 * Options
 * ETFs


TOOLS & FEATURES

 * Real Time Feed
 * Public RSS Feeds
 * Submit News Tips
 * Blog
 * Embeddable Finance Widgets & Tools
 * Benzinga Catalyst


PARTNERS & CONTRIBUTORS

 * Affiliate Program
 * Contributor Portal
 * Licensing & Syndication
 * Sponsored Content
 * Advertise With Us
 * Lead Generation & SEO


ABOUT BENZINGA

 * About Us
 * Careers
 * In The News
 * Events
 * Contact Us

 * Terms & Conditions
 * Do Not Sell My Personal Data/Privacy Policy
 * Disclaimer
 * Service Status
 * Sitemap

© 2024 Benzinga | All Rights Reserved






✕
Do not sell or share my personal information.
You have chosen to opt-out of the sale or sharing of your information from this
site and any of its affiliates. To opt back in please click the "Customize my ad
experience" link.

This site collects information through the use of cookies and other tracking
tools. Cookies and these tools do not contain any information that personally
identifies a user, but personal information that would be stored about you may
be linked to the information stored in and obtained from them. This information
would be used and shared for Analytics, Ad Serving, Interest Based Advertising,
among other purposes.

For more information please visit this site's Privacy Policy.
CANCEL
CONTINUE

Information from your device can be used to personalize your ad experience.

Do not sell or share my personal information.